Kenny Fan

Experience

• 

  Pfizer

  Dec 2011 - Jan 2017

  In charge of GU & CV Portfolio which includes Doxaben, Detrusitol, Caduet and GP/DH Channel Strategy in Taiwan• Consolidate market leadership of Doxaben / Detrusitol in LUTS and Caduet in CVD. In charge of various TAs which includes CV, GU, Pain, Vaccine & Smoke Cessation, Oncology & Ophthalmology in MC/DH/GP/DS channel• KOLs / KDMs management which includes clinicians, pharmacy, procurement team and pharmaceutical committee.• Sales Excellence with customized approach to optimize channel management.

  • Country Portfolio Manager

    Dec 2015 - Jan 2017

  • Sr. Professional Sales Representative / Professional Sales Representative

    Dec 2011 - Nov 2015
• 

  Novartis Oncology

  Jan 2017 - Sept 2022

  In charge of Cell & Gene unit and be accountable for optimizing BU P&L with operational excellence.• Lead new business model set up for Kymriah commercial launch readiness with whole cross-functional team.• Strive for P&L delivery and be accountable to establish an agile High Performance Team. In charge of RCC/STS Portfolio, including Marketing and Sales function.• Develop strategic product planing with integrated action items to sustain future success in our long run.• Lead national sales team directly and be accountable for delivering business outcome. In charge of Cell and Gene Therapy & Rare tumor which includes Kymriah, Lutathera / Lysakare, Sandostatin LAR, Afinitor, Signifor Group and TAF-MEK in Taiwan• Well-experienced in new product launch preparation and NHIA reimbursement expansion.• Develop innovative approach with marketing excellence to expedite business expansion.• Successful turn-around business result under facing highly competition from new competitor.

  • Commercial Lead, Cell & Gene Therapy

    Feb 2021 - Sept 2022

  • Business Manager

    Jul 2020 - Jun 2021

  • Sr. Product Manager / Product Manager

    Jan 2017 - Jun 2020
• 

  諾華公司

  Oct 2022 - now

  Lead national sales team and ensure business impact delivery. Lead Value & Access / NPP team on supporting IMTW to achieve business objectives. • Ensure reimbursement of novel medicine and indication expansion. 8 cases are granted by NHIA in Y23-Y24.• Shaping policy environment collaboratively with cross functional team and industrial association. • Horizon scanning on pipeline to prioritize and maximize country portfolio integration with adequate investment.

  • Sales Head, Solid Tumor

    Nov 2024 - now

  • Value & Access Lead, IMTW

    Oct 2022 - Oct 2024